LATEST NEWS
Royal Society President Sir Paul Nurse Visits Chinese Academy Of Sciences
President of the Royal Society Sir Paul Nurse gave a lecture at the University of the Chinese Academy of Sciences during his first official visit to China.
Luqa Pharma, Stratpharma Extend Collaboration In China
Stratpharma and Luqa Pharma have extended their collaboration past 2020 in the areas of cosmetic dermatology, plastic surgery, burns, wounds and scar management.
BGI Tech To Collaborate On San Antonio 1000 Cancer Genome Project
BGI Tech and South Texas Accelerated Research Therapeutics are collaborating on the San Antonio 1000 Cancer Genome Project.
MicroConstants China Licenses Liver Cancer Drug From Pertinax Therapeutics
MicroConstants China Inc. has licensed the China rights for a Phase II liver cancer drug candidate, PTX-9908, from Pertinax Therapeutics of Canada.
Servier, A*STAR To Develop Drugs That Target Immune System
French pharmaceutical company Servier has inked three Research Collaboration Agreements with A*STAR's Singapore Immunology Network.
Servier To License Lucitanib To SIMM In China
Servier and the Shanghai Institute of Materia Medica will collaborate on the development of lucitanib, a targeted antitumor drug candidate with anti-angiogenic effects, in China.
Ironwood, AstraZeneca Initiate Linaclotide PhIII Trial In China
Ironwood and AstraZeneca have initiated a Phase III clinical trial of linaclotide for the treatment of adults with irritable bowel syndrome with constipation.
Reduction In Greenhouse Gases Could Save Chinese Lives, Study
Global abatement of greenhouse gas emissions could save between 0.3-0.7 million premature deaths in the year 2030, two-thirds of which would be in China, reports a new study.
Norgine, Takeda Receive NDA Approval For OBLEAN Tablets 120mg In Japan
The Japanese Ministry of Health, Labor and Welfare has approved an NDA for OBLEAN® Tablets 120mg for the treatment of obesity with complications.
